Sorafenib can interfere the transduction of extracellular-signal-regulated kinase (ERK) signaling and inhibit cancer cell proliferation through downregulating the expression of the isoforms of serine/threonine kinases Raf, Raf-1, and B-Raf (3). Here, RAF1 is linked to cancer.